 | |
| Clinical data | |
|---|---|
| Other names | Valiloxibic acid; Valiloxybic acid; 4-((L-Valyl)oxy)butanoic acid; XW-10172; XW10172; XWL-008; XWL008 |
| Routes of administration | Oral[1] |
| Drug class | GABAB receptoragonist;GHB receptoragonist;Hypnotic |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C9H17NO4 |
| Molar mass | 203.238 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Valiloxybate (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name;[2] developmental code nameXW-10172) is anextended-releaseprodrug ofγ-hydroxybutyrate (GHB; oxybate) which is under development for the treatment ofnarcolepsy.[1][3][4][5][6] It is also being investigated for treatment ofexcessive daytime sleepiness (EDS) in people withParkinson's disease.[7] The drug is takenorally once per night.[1][4][5][8][6]
It is anamino acid (L-valine)ester prodrug of GHB,[6][2] which itself acts as aGABAB andGHB receptoragonist.[9][10] Relative to administration of GHB itself, valiloxybate showed a delayedtime to peak levels and an extendedduration of GHB exposure in humans.[6] It is said to maintain desired GHB levels for 6 to 7 hours.[11] This profile is compatible with once-nightly dosing,[6] in contrast to GHB itself which is typically administered twice per night due to its very shortelimination half-life.[12][13][14] In addition, unlikesodium oxybate, valiloxybate contains nosodium orcation, and hence avoids excessive sodium intake.[6][15]
Valiloxybate is under development by XW labs or XWPharma.[1] As of September 2025, no recent development has been reported, but valiloxybate has reachedphase 1clinical trials for treatment of narcolepsy andphase 2 trials for treatment of sleeping problems in Parkinson's disease.[1][7]